Company Profile

DiaMedica Therapeutics Inc. is a publicly traded, clinical stage biopharmaceutical company primarily focused on large unmet diseases including novel approaches to treat neurological and kidney diseases.

Our lead compound, DM199, is currently in a Phase II clinical trial for ischemic stroke with plans to initiate trials in chronic kidney disease in early 2018. To date, we have completed 5 clinical trials in over 130 patients.